Biohaven Ltd. (NYSE:BHVN) Shares Acquired by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC grew its holdings in Biohaven Ltd. (NYSE:BHVN - Free Report) by 2,952.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 12,180 shares of the company's stock after buying an additional 11,781 shares during the quarter. Tower Research Capital LLC TRC's holdings in Biohaven were worth $455,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in BHVN. Spire Wealth Management bought a new position in Biohaven during the 4th quarter valued at approximately $56,000. Amalgamated Bank raised its holdings in Biohaven by 21.9% in the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after acquiring an additional 527 shares during the last quarter. US Bancorp DE boosted its position in shares of Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after buying an additional 798 shares during the last quarter. Elkhorn Partners Limited Partnership boosted its holdings in shares of Biohaven by 50.0% during the 4th quarter. Elkhorn Partners Limited Partnership now owns 3,300 shares of the company's stock valued at $123,000 after acquiring an additional 1,100 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of Biohaven by 50.1% in the fourth quarter. KBC Group NV now owns 3,377 shares of the company's stock worth $126,000 after acquiring an additional 1,127 shares during the period. 88.78% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director John W. Childs purchased 32,700 shares of the stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the acquisition, the director now owns 2,320,571 shares of the company's stock, valued at approximately $70,707,798.37. This represents a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BHVN. Robert W. Baird decreased their target price on shares of Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a research note on Monday, April 28th. Morgan Stanley lowered their target price on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the company a "buy" rating in a research note on Thursday, March 20th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 target price on shares of Biohaven in a report on Tuesday, March 4th. Finally, William Blair upgraded Biohaven to a "strong-buy" rating in a research report on Thursday, April 24th. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Biohaven has an average rating of "Buy" and an average target price of $62.54.

Biohaven Price Performance

Shares of NYSE:BHVN traded up $0.03 during trading on Monday, hitting $22.88. The company had a trading volume of 117,210 shares, compared to its average volume of 1,152,998. Biohaven Ltd. has a one year low of $15.79 and a one year high of $55.70. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -2.45 and a beta of 1.18. The company has a fifty day simple moving average of $24.91 and a two-hundred day simple moving average of $36.37.

Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). On average, equities research analysts anticipate that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.